When a child is diagnosed with cancer, one of the first questions the parents ask is "Will my other children get cancer?" A new study from Huntsman Cancer Institute (HCI) at the University of Utah, a member of the National Comprehesive Network (NCCN), suggests the answer to that question depends on whether a family history of cancer exists. The research results were…Continue
Added by Editorial Team on August 7, 2013 at 5:30pm — No Comments
The U.S. Supreme Court heard arguments Monday in a case seeking to invalidate patents on two genes associated with hereditary breast and ovarian cancer. The American College of Medical Genetics and Genomics (ACMG) was one of the first plaintiffs to sign onto this historic legal case.
The American College of Medical Genetics and Genomics was also the first professional medical association to establish a position…Continue
Added by Editorial Team on April 17, 2013 at 2:30pm — No Comments
According to researchers, initial phase I, first in-human, trial results for TKM-080301, also known as TKM-PLK1, indicate that a potential new class of drugs called RNA interference (RNAi) drugs, can be safely administered in humans. The early results for the drug, which is being developed by Tekmira Pharmaceuticals Corporation, were presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10, 2013.
Commenting on the early trial results, Ramesh K.…Continue
Added by Editorial Team on April 9, 2013 at 5:30pm — No Comments
MicroRNAs are short non-coding RNAs that posttranscriptionally modulate the expression of multiple target genes. They are implicated in a wide range of cellular and developmental processes. The microRNA (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, is highly expressed in both activated B and T cells and in monocytes/macrophages. Research has shown that miR-155 levels change dynamically during both hematopoietic lineage differentiation and the…Continue
Added by Peter Hofland, PhD on April 1, 2013 at 4:00pm — No Comments
Researchers at the Translational Genomics Research Institute (TGen) and its collaborators have identified a rare, inherited mutation linked to a significantly higher risk of prostate cancer.
A study led by Johns Hopkins University School of Medicine and the University of Michigan…
Added by Peter Hofland, PhD on January 11, 2012 at 5:30pm — No Comments
Added by Peter Hofland, PhD on February 24, 2011 at 11:30am — No Comments
For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn't been clear, however, is how the body's genome sustains such destructive glitches in the first place. Now a team of scientists and research collaborators at the Mayo Clinic provide an unprecedented glimpse of a little-understood gene, called MMSET, revealing how it enables…Continue
Added by Peter Hofland, PhD on February 2, 2011 at 5:30pm — No Comments
Molecular staging or genomic profiling holds promise in predicting the long-term outcome of an individual patient based on the gene expression profile of their cancer at diagnosis. Researchers have shown that a gene signature test – called ColoPrint – that analyzes the expression of 18 genes can identify the risk of recurrence in colorectal cancer patients with localized, stage II disease.
Such a gene signature test could have important implications for…
Added by Peter Hofland, PhD on January 22, 2011 at 4:30pm — No Comments
Added by Peter Hofland, PhD on December 1, 2010 at 11:00am — No Comments
Added by Peter Hofland, PhD on November 29, 2010 at 11:30am — No Comments